34
Participants
Start Date
March 7, 2019
Primary Completion Date
August 6, 2019
Study Completion Date
August 6, 2019
Placebo IV infusion
Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
Iloprost Injection, for intravenous use
Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
Hospital for Special Surgery, New York
Columbia University Medical Center, New York
University of Pittsburgh Medical Center, Pittsburgh
Georgetown University Medical Center - Department of Rheumatology, Washington D.C.
Johns Hopkins University School of Medicine, Baltimore
The University of Toledo Medical Center (UTMC) - Ruppert Health Center, Toledo
Cleveland Clinic, Cleveland
University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics, Houston
Arizona Arthritis & Rheumatology Research, PLLC, Phoenix
Pacific Arthritis Care Center of Los Angeles, Los Angeles
University of California San Francisco, San Francisco
Stanford University Medical Center, Palo Alto
Virginia Mason Medical Center, Seattle
Arthritis Northwest Rheumatology PLLC, Spokane
University of Michigan, Ann Arbor
Robert Wood Johnson Medical School, New Brunswick
Lead Sponsor
Civi Biopharma, Inc.
INDUSTRY